N-[(1S)-5-Amino-1-cyano-pentyl]-2-[[3-(4-fluorophenyl)-2,5-dioxo-imidazolidin-1-yl]methyl]-3-methylbenzimidazole-5-carboxamide

ID: ALA3585742

Chembl Id: CHEMBL3585742

PubChem CID: 122179839

Max Phase: Preclinical

Molecular Formula: C25H26FN7O3

Molecular Weight: 491.53

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  Cn1c(CN2C(=O)CN(c3ccc(F)cc3)C2=O)nc2ccc(C(=O)N[C@H](C#N)CCCCN)cc21

Standard InChI:  InChI=1S/C25H26FN7O3/c1-31-21-12-16(24(35)29-18(13-28)4-2-3-11-27)5-10-20(21)30-22(31)14-33-23(34)15-32(25(33)36)19-8-6-17(26)7-9-19/h5-10,12,18H,2-4,11,14-15,27H2,1H3,(H,29,35)/t18-/m0/s1

Standard InChI Key:  CBEUWSCJKHKODR-SFHVURJKSA-N

Alternative Forms

  1. Parent:

    ALA3585742

    ---

Associated Targets(Human)

PLAU Tchem Urokinase-type plasminogen activator (2016 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLG Tclin Plasminogen (2339 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 491.53Molecular Weight (Monoisotopic): 491.2081AlogP: 2.43#Rotatable Bonds: 9
Polar Surface Area: 137.35Molecular Species: BASEHBA: 7HBD: 2
#RO5 Violations: HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.34CX Basic pKa: 10.20CX LogP: 1.15CX LogD: -1.45
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.35Np Likeness Score: -1.52

References

1. Teno N, Gohda K, Wanaka K, Tsuda Y, Akagawa M, Akiduki E, Araki M, Masuda A, Otsubo T, Yamashita Y..  (2015)  Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.,  23  (13): [PMID:25921265] [10.1016/j.bmc.2015.04.013]
2. Teno N, Gohda K, Yamashita Y, Otsubo T, Yamaguchi M, Wanaka K, Tsuda Y..  (2016)  Plasmin inhibitors with hydrophobic amino acid-based linker between hydantoin moiety and benzimidazole scaffold enhance inhibitory activity.,  26  (9): [PMID:27009905] [10.1016/j.bmcl.2016.03.047]

Source